Site selection still runs on relationships and best guesses, and identification drags on for months. Theranostix lets you target qualified centres by molecular target, country and demonstrated capability, using real activity signals instead of assumptions.
In a field as specialised as radioligand therapy, the pool of capable sites is narrow and unevenly documented. Feasibility teams burn months assembling shortlists, and some selected sites never enrol — a cost measured in quarters, not weeks.
Building a credible site shortlist across nine countries and six languages is manual and time-consuming.
Selection leans on who you know, not on demonstrated activity in the relevant target and indication.
Without capability evidence, shortlists include centres that look right on paper but can’t deliver.
Filter centres by target, isotope, country and demonstrated theranostics activity — not just registry presence.
See where similar RLT trials have run and which sites have been active in your space.
Build a qualified shortlist with the evidence behind each site, ready to share with your team or CRO.
Not sure which tier fits? We’ll scope it with you.
Contact salesA 30-minute walkthrough, tailored to you — or talk to sales about a license.
Book an intelligence walkthroughContact sales